Stock DNLI DENALI THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 11:41:49 2024-04-26 am EDT 		5-day change 1st Jan Change
15.25 USD +1.94% Intraday chart for Denali Therapeutics Inc. -4.16% -28.54%
Apr. 09 UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating MT
Apr. 03 Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing MT

Business Summary

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).

Number of employees: 445

Sales per Business

USD in Million2022Weight2023Weight Delta
Therapeutics
100.0 %
108 100.0 % 331 100.0 % +204.74%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
108 100.0 % 331 100.0 % +204.74%

Managers

Managers TitleAgeSince
Alexander Schuth FOU
 Founder 50 13-10-13
Ryan Watts FOU
 Founder 48 13-10-13
Joe Lewcock CTO
 Chief Tech/Sci/R&D Officer - 19-12-31
Dana Andersen CTO
 Chief Tech/Sci/R&D Officer - 18-08-06
Carole Ho CTO
 Chief Tech/Sci/R&D Officer 51 15-05-31
Steve Krognes BRD
 Director/Board Member 56 15-09-30
Laura G. Hansen IRC
 Investor Relations Contact - -
Katie Peng PRN
 Corporate Officer/Principal - 21-09-26
Erica Kratz LAW
 General Counsel - -
Chris Walsh LAW
 General Counsel - -

Members of the board

Members of the board TitleAgeSince
Vicki Sato CHM
 Chairman 75 15-03-31
Jay Flatley BRD
 Director/Board Member 71 15-03-31
David Schenkein BRD
 Director/Board Member 66 15-03-31
Marc Tessier-Lavigne FOU
 Founder 64 13-10-13
Jennifer Cook BRD
 Director/Board Member 58 18-11-05
Peter Klein BRD
 Director/Board Member 61 18-03-15
Erik Harris BRD
 Director/Board Member 54 22-02-06
Steve Krognes BRD
 Director/Board Member 56 15-09-30
Nancy Thornberry BRD
 Director/Board Member 67 21-01-07
Ryan Watts FOU
 Founder 48 13-10-13

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 142,539,529 122,839,616 ( 86.18 %) 0 86.18 %

Shareholders

NameEquities%Valuation
Baillie Gifford & Co.
10.25 %
14,260,724 10.25 % 293 M $
BIOGEN INC.
9.163 %
12,751,365 9.163 % 262 M $
Vanguard Fiduciary Trust Co.
7.786 %
10,834,483 7.786 % 222 M $
BlackRock Advisors LLC
7.607 %
10,585,444 7.607 % 217 M $
Wellington Management Co. LLP
5.228 %
7,274,717 5.228 % 149 M $
Temasek Holdings Pte Ltd.
4.955 %
6,895,992 4.955 % 142 M $
Crestline Management LP
4.068 %
5,660,732 4.068 % 116 M $
STATE STREET CORPORATION
3.942 %
5,485,948 3.942 % 113 M $
TAKEDA PHARMACEUTICAL COMPANY LIMITED
3.029 %
4,214,559 3.029 % 86 M $
Capital Research & Management Co. (Global Investors)
2.091 %
2,909,528 2.091 % 60 M $

Company contact information

Denali Therapeutics, Inc.

161 Oyster Point Boulevard

94080, San Francisco

+650 866 8548

http://www.denalitherapeutics.com
address Denali Therapeutics Inc.(DNLI)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Denali Therapeutics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
14.96 USD
Average target price
40.27 USD
Spread / Average Target
+169.16%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
DENALI THERAPEUTICS INC. Stock Denali Therapeutics Inc.
-30.29% 2.13B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.26% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.41% 95.71B
ARGENX SE Stock argenx SE
+0.73% 22.02B
BIONTECH SE Stock BioNTech SE
-17.84% 20.9B
GENMAB A/S Stock Genmab A/S
-9.26% 17.85B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.83% 16.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.63% 15.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.55% 13.86B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+32.11% 12.04B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. DNLI Stock
  4. Company Denali Therapeutics Inc.